alexa
Reach Us +44-1235-425476
New Biodegradable Nanoparticle Systems For The Treatment Of Chronic Lymphocytic Leukemia And Lymphomas | 7855
ISSN : 2153-2435

Pharmaceutica Analytica Acta
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

New biodegradable nanoparticle systems for the treatment of chronic lymphocytic Leukemia and lymphomas

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Eduardo Mansilla

ScientificTracks Abstracts: PAA

DOI: 10.4172/2153-2435.10000S4

Abstract
Nonviral delivery systems are relatively easy to produce in the large scale, are safe, and elicit a negligible immune response. Nanoparticles (NPs) off er promise as nonviral vectors as biocompatible and -degradable carriers of drugs with targeting capacities to specifi c cell sites by surface receptors of monoclonal antibodies (mAbs). We present the eff ect of Biodegradable NP systems on drug- resistant B-chronic lymphocytic leukemia (B-CLL) cells in vitro, encapsulating the drug, hydroxylchloroquine (HDQ), with NP surface coatings of specifi c Monoclonals Antibodies such as the anti human CD20 mAb, Rituximab. Our data indicate that these nanoparticles with surface mAbs are suitable for selective drug delivery to B-CLL cells and other lymphoma cell lines, producing a strong apoptotic eff ect when loaded with the lysosomotropic agent, HDQ. We also evaluated their toxic and therapeutic eff ects on a Human/Mouse Model of Burkitt Lymphoma, adding this time Chlorambucil to the system. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. Th e mediated cytotoxicity resulted from apoptosis, and was confi rmed by monitoring the B-CLL cells aft er Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged an outstanding survival in this mice model of human lymphoma.
Biography
rof. Eduardo Ra?l Mansilla is a Medical Doctor graduated from the School of Medicine of the National University of La Plata, Argentina, in 1979. Senior Specialist in Internal Medicine. Professor of Internal Medicine of the School of Medicine, National University of La Plata Argentina. Former Vice Director Spanish Hospital La Plata Argentina. Vice President Argentine Federation of Internal Medicine (FAMI). Former President, La Plata Society of Internal Medicine. Former President, La Plata Society of Cancerology. Former Coordinator Argentine Diabetes Society Immunology and Genetic Commeettee. Director, Laboratory of Tissue Engineering, Regenerative Medicine and Cell Therapies of CUCAIBA La Plata Province of Buenos Aires Ministry of Health Center of Procurement and Transplantation of Organs. First Prize Argentine Haematology Society 2007 for the Research Paper ? Biodegradable Nanoparticles with Chlorambucil and Hydroxychloroquine for the Treatment of Chronic Lymphocytic Leukemia?.
Top